<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417911</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG 15/05</org_study_id>
    <secondary_id>EudraCT No: 2005-002756-18</secondary_id>
    <nct_id>NCT00417911</nct_id>
  </id_info>
  <brief_title>Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients</brief_title>
  <official_title>Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Myeloma Study Group</source>
  <brief_summary>
    <textblock>
      Multiple myeloma is a malignant incurable hematological disease where survival has been
      significantly improved by high-dose melphalan with autologous stem cell support (ASCT) in
      younger patients. However, the disease will eventually relapse and new treatment is demanded.
      Bortezomib is a newly approved drug for treating relapsing multiple myeloma. It has a
      different biological effect and response even in patients refractory to conventional
      chemotherapy. The purpose of the study is in a randomized design to investigate if addition
      of bortezomib by 20 injections during a 4 months period starting 3 month after ASCT can
      prolong the time to progression compared to patients receiving no consolidation or
      maintenance therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      ASCT prolongs EFS and OS for myeloma patients &lt; 65 years of age. During the period from ASCT
      to progression most myeloma patients experience few symptoms and have a good quality of
      life11. A further prolongation of EFS would be a big step forward in myeloma treatment.
      Bortezomib is a new promising agent, which has shown clear anti-myeloma effect in heavily
      pre-treated patients. After ASCT the tumour cell burden is low and it is the hypothesis of
      this clinical trial that the unique mechanism of action of bortezomib may reduce the number
      of tumour cells even further and by doing so prolong EFS.

      Primary objective:

      * Evaluate the effect on EFS (an event is defined as either progression or death of any cause
      without preceding progression) of consolidation treatment with bortezomib after ASCT compared
      to no consolidation

      Secondary objectives:

        -  Overall survival from ASCT

        -  Overall survival from start of relapse treatment

        -  Time to need for relapse treatment

        -  Response rate in patients not in CR following ASCT

        -  Toxicity from consolidation treatment

        -  Quality of life

        -  Cost utility

        -  Planned subgroup analysis: comparison of primary and secondary endpoint in patients
           receiving one vs. two high dose treatments
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect on EFS (an event is defined as either progression or death of any cause without preceding progression) of consolidation treatment with bortezomib after ASCT compared to no consolidation</measure>
    <time_frame>1 year after randomization of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival from ASCT</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from start of relapse treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to need for relapse treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in patients not in CR following ASCT</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity from consolidation treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost utility</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned subgroup analysis: comparison of primary and secondary endpoint in patients receiving one vs. two high dose treatments</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib consolidation : 20 injections starting 3 months after ASCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles</description>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_label>Bortezomib consolidation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic myeloma diagnosis according to criteria in attachment 3

          -  ASCT is performed or has been performed in the last five weeks (time limit two weeks
             for patients randomised at 2nd transplantation) as a part of primary therapy

          -  Signed informed consent given prior to any study related activities have been
             performed

        Exclusion Criteria:

          -  Prior exposure to bortezomib

          -  Allogeneic transplantation scheduled as a part of the primary treatment

          -  Neuropathy &gt; Grade 2 (neurological symptoms interfering with ADL)

          -  Non-secreting myeloma

          -  Other concurrent disease making bortezomib treatment unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin,
             if an indwelling catheter is used

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

          -  History of hypotension or has decreased blood pressure (sitting systolic blood
             pressure [SBP] £100 mmHg and/or sitting diastolic blood pressure [DBP] £60 mmHg)

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Have received an experimental drug or used an experimental medical device within 4
             weeks prior to inclusion into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf-Henrik Mellqvist, Dr., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NMSG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hæmatologisk afdeling L Amtssygehuset i Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinsk Hæmatologisk afd L4042, Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk afd X, Odense Universitetshospital</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk afdeling B, Aalborg Sygehus Syd</name>
      <address>
        <city>Ålborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk afd. B, Århus Universitetshospital, Amtssygehuset</name>
      <address>
        <city>Århus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Dep 10a</name>
      <address>
        <city>Tampere</city>
        <zip>SF-33 521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Dept. of Medicine, PL 52,</name>
      <address>
        <city>Turku</city>
        <zip>SF-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemathology department, University State Hospital, Landspitali</name>
      <address>
        <city>Reykjavik</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk seksjon, med avd, Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seksjon for blodsykdommer, Med. avd.,Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N - 0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk avdeling Ullevål Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N - 0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge</name>
      <address>
        <city>Tromsø</city>
        <zip>N-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisk seksjon Regionssykehuset</name>
      <address>
        <city>Trondheim</city>
        <zip>N - 7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologiska klin, Huddinge sjukhus</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologkliniken, Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklin, Universitetssjukhuset MAS,</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinklin, Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Universitetssjukhuset</name>
      <address>
        <city>Örebro</city>
        <zip>SE-70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.nordic-myeloma.org</url>
    <description>NMSG home page</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ulf-Henrik Melqvist</name_title>
    <organization>Nordic Myeloma Study Group, Sahlgrenska University Hospital Gothenborg</organization>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>high-dose melphalan</keyword>
  <keyword>bortezomib</keyword>
  <keyword>consolidation</keyword>
  <keyword>event free survival</keyword>
  <keyword>phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

